TLX-050

TLX-050 is an investigational drug candidate currently in development for the treatment of **neurological system disorders**. The program is being advanced through a co-development collaboration between **Easywell Biomedical** (via its subsidiary **Tulex Pharmaceuticals**), **Handa Biotechnology** (via **Handa Neuroscience**), and an undisclosed third-party pharmaceutical company. According to the partnership terms established in late 2024, Easywell and Tulex are responsible for the early-stage development of the asset and will receive milestone payments. Upon potential FDA approval, Tulex Pharmaceuticals is designated to handle the manufacturing of the product, while the unnamed third-party partner will manage distribution within agreed territories. As of the most recent updates, specific details regarding the drug's molecular modality, biological target, and exact mechanism of action have not been publicly disclosed.